Skip to main content

Diskets News

Hospital Addiction Consultation Service Aids Opioid Use Disorder

WEDNESDAY, April 16, 2025 – A hospital-based addiction consultation service can improve receipt of evidence-based treatment for people with opioid use disorder (OUD), according to a study published...

Methadone Tied to Lower Risk for Discontinuation Versus Buprenorphine/Naloxone

FRIDAY, Oct. 18, 2024 – Receipt of methadone for opioid use disorder is associated with a lower risk for treatment discontinuation compared with buprenorphine/naloxone, according to a study...

Inmates in Many U.S. Jails Have No Access to Meds That Fight Opioid Addiction

TUESDAY, Sept. 24, 2024 – Opioid use disorder can be a contributing factor to Americans landing in the nation's prisons and jails, but those inmates typically have no access to medications that...

Acupuncture Can Reduce Methadone Dose, Opioid Craving

MONDAY, July 8, 2024 – For individuals with opioid use disorder receiving methadone maintenance treatment (MMT), eight weeks of acupuncture is superior to sham acupuncture for reducing methadone...

FDA Medwatch Alert: Opioid Addiction Medications in Patients Taking Benzodiazepines or CNS Depressants: Drug Safety Communication - Careful Medication Management Can Reduce Risks

ISSUE: Based on additional review, FDA is advising that the opioid addiction medications buprenorphine and methadone should not be withheld from patients taking benzodiazepines or other drugs that...

FDA Medwatch Alert: Opioid Pain or Cough Medicines Combined With Benzodiazepines: Drug Safety Communication - FDA Requiring New Boxed Warnings About Serious Risks and Death

ISSUE: FDA review has found that the growing combined use of opioid medicines with benzodiazepines or other drugs that depress the central nervous system (CNS) has resulted in serious side effects,...

FDA Medwatch Alert: Opioid Pain Medicines: Drug Safety Communication - New Safety Warnings Added to Prescription Opioid Medications

ISSUE: FDA is warning about several safety issues with the entire class of opioid pain medicines. See the FDA Drug Safety Communication for a complete listing. These safety risks are potentially h...

FDA Medwatch Alert: Compounded Drugs Stored in Becton-Dickinson (BD) 3 ml and 5 ml Syringes: FDA Warning - Do Not Use

ISSUE: FDA is alerting health care professionals not to administer to patients compounded or repackaged drugs that have been stored in 3 milliliter (ml) and 5ml syringes manufactured by...

FDA Medwatch Alert: Methadone Hydrochloride (dolophine)

Indication: Treatment of moderate to severe pain not responsive to non-narcotic analgesics; detoxification of opioid addiction; and maintenance treatment of opioid addiction [Posted 11/27/2006] FDA...

FDA Medwatch Alert: Dolophine (methadone hydrochloride)

Indication: Treatment of moderate to severe pain not responsive to non-narcotic analgesics; detoxification of opioid addiction; and maintenance treatment of opioid addiction[Posted 11/27/2006] FDA...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Chronic Pain, Opiate Withdrawal, Pain

Diskets patient information at Drugs.com